- Home
- SOR vs DSGN Comparison
SOR vs DSGN Comparison
Compare SOR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- DSGN
- Stock Information
- Founded
- SOR 1968
- DSGN 2017
- Country
- SOR United States
- DSGN United States
- Employees
- SOR N/A
- DSGN 54
- Industry
- SOR Investment Managers
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- DSGN Health Care
- Exchange
- SOR Nasdaq
- DSGN Nasdaq
- Market Cap
- SOR 361.3M
- DSGN 353.9M
- IPO Year
- SOR N/A
- DSGN 2021
- Fundamental
- Price
- SOR $45.26
- DSGN $6.39
- Analyst Decision
- SOR
- DSGN Hold
- Analyst Count
- SOR 0
- DSGN 3
- Target Price
- SOR N/A
- DSGN $7.00
- AVG Volume (30 Days)
- SOR 16.2K
- DSGN 156.0K
- Earning Date
- SOR 01-01-0001
- DSGN 11-07-2024
- Dividend Yield
- SOR 7.24%
- DSGN N/A
- EPS Growth
- SOR N/A
- DSGN N/A
- EPS
- SOR 6.50
- DSGN N/A
- Revenue
- SOR N/A
- DSGN N/A
- Revenue This Year
- SOR N/A
- DSGN N/A
- Revenue Next Year
- SOR N/A
- DSGN N/A
- P/E Ratio
- SOR $6.41
- DSGN N/A
- Revenue Growth
- SOR N/A
- DSGN N/A
- 52 Week Low
- SOR $36.41
- DSGN $2.25
- 52 Week High
- SOR $42.75
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- SOR 54.60
- DSGN 51.81
- Support Level
- SOR $44.00
- DSGN $5.16
- Resistance Level
- SOR $45.47
- DSGN $6.43
- Average True Range (ATR)
- SOR 0.65
- DSGN 0.50
- MACD
- SOR -0.05
- DSGN -0.03
- Stochastic Oscillator
- SOR 49.57
- DSGN 56.08
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.